NanoViricides, Inc. Announces Renewal of DengueCide Evaluation Contract With the Professor Eva Harris Laboratory at the University of California, Berkeley (CAL)
Published: Nov 04, 2013
WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (NYSE MKT:NNVC) (the "Company"), announced today that theDengueCide evaluation contract has been renewed with Dr. Eva Harris’ Laboratory at the University of California, Berkeley, School of Public Health, Division of Infectious Diseases and Vaccinology. Dr. Harris is one of the world’s leading experts in dengue. This contract renewal will allow the Company to continue its drug development program for the treatment of dengue.
Help employers find you! Check out all the jobs and post your resume.